AstraZeneca has filed a patent for technologies enhancing AAV vector production. The claim specifies a Rep/Helper plasmid with a specific polynucleotide sequence, excluding a cap gene. GlobalData’s report on AstraZeneca gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights AstraZeneca Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AstraZeneca, Personalized cancer vaccines was a key innovation area identified from patents. AstraZeneca's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Improved production of aav vectors using specific plasmid sequence

Source: United States Patent and Trademark Office (USPTO). Credit: AstraZeneca Plc

A recently filed patent (Publication Number: US20240035047A1) discloses a Rep/Helper plasmid containing specific polynucleotide sequences (SEQ ID NO: 1 and SEQ ID NO: 2) that do not encode a cap gene. Additionally, the patent claims a composition comprising this plasmid along with a Payload/Cap plasmid (SEQ ID NO: 11) that lacks a polynucleotide sequence encoding a rep gene. The Payload/Cap plasmid includes a sequence encoding a cap gene selected from a wide range of AAV variants.

Furthermore, the patent details the insertion positions of the cap gene sequence within the Payload/Cap plasmid and the encoding of a payload transgene at specific positions. The transgene can be selected from a list of genes provided in the patent, including variants thereof. The composition is limited to no more than two distinct plasmids, with a specific ratio between the Rep/Helper plasmid and the Payload/Cap plasmid. The disclosed composition is intended for use in producing an AAV vector, and a method for manufacturing a packaged AAV vector involving the delivery of this composition to a cell is also described, with the optional use of a chemical transfection reagent.

To know more about GlobalData’s detailed insights on AstraZeneca, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies